Raloxifene Suppresses Tumor Growth and Metastasis in an Orthotopic Model of Castration-Resistant Prostate Cancer

Androgen receptor (AR)-castrate-resistant prostate cancer (CRPC) is an aggressive form of prostate cancer that does not have clinically approved targeted treatment options. To this end, the cytotoxic potential of raloxifene and the synthetic curcumin derivative 2,6-bis (pyridin-4-ylmethylene)-cycloh...

Descripción completa

Detalles Bibliográficos
Autores principales: Palmer, Hannah, Nimick, Mhairi, Mazumder, Aloran, Taurin, Sebastien, Rana, Zohaib, Rosengren, Rhonda J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033055/
https://www.ncbi.nlm.nih.gov/pubmed/35453603
http://dx.doi.org/10.3390/biomedicines10040853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033055/
https://www.ncbi.nlm.nih.gov/pubmed/35453603
http://dx.doi.org/10.3390/biomedicines10040853

Ejemplares similares